MCID: JVN009
MIFTS: 39

Juvenile Pilocytic Astrocytoma malady

Categories: Cancer diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Juvenile Pilocytic Astrocytoma

About this section

Aliases & Descriptions for Juvenile Pilocytic Astrocytoma:

Name: Juvenile Pilocytic Astrocytoma 10 47 12 65

Classifications:



External Ids:

Disease Ontology10 DOID:6811
MeSH36 D001254
NCIt42 C27081
UMLS65 C0280783

Summaries for Juvenile Pilocytic Astrocytoma

About this section
MalaCards based summary: Juvenile Pilocytic Astrocytoma is related to pilocytic astrocytoma and compartment syndrome. An important gene associated with Juvenile Pilocytic Astrocytoma is TNC (Tenascin C), and among its related pathways are Osteopontin Signaling and G-protein signaling M-RAS regulation pathway. Affiliated tissues include brain, liver and kidney, and related mouse phenotypes are hearing/vestibular/ear and tumorigenesis.

Related Diseases for Juvenile Pilocytic Astrocytoma

About this section

Diseases in the Pilocytic Astrocytoma family:

juvenile pilocytic astrocytoma

Diseases related to Juvenile Pilocytic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 143)
idRelated DiseaseScoreTop Affiliating Genes
1pilocytic astrocytoma33.9NF1, TP53
2compartment syndrome10.5NF1, ZBTB20
3alveoli adenoma10.5GFAP, TP53
4complement component 3 deficiency10.4GFAP, NF1
5spinal cord astrocytoma10.4CDKN2A, TP53
6ovarian mucinous cystadenofibroma10.4GFAP, TP53
7deep leiomyoma10.4CDKN2A, TP53
8congenital disorder of glycosylation, type if10.4GFAP, TP53
9splenogonadal fusion limb defects micrognatia10.4CDKN2A, TP53
10basaloid squamous cell carcinoma10.4CDKN2A, TP53
11cerebellar medulloblastoma10.4GFAP, TP53
12childhood infratentorial neoplasm10.4GFAP, TP53
13lateral ventricle meningioma10.4GFAP, TP53
14tuberculous empyema10.4CDKN2A, MBP
15space motion sickness10.4GFAP, TP53
16adult choroid plexus cancer10.3GFAP, TP53
17pineal gland astrocytoma10.3GFAP, NF1, TP53
18myotonia congenita10.3CDKN2A, TP53
19follicular basal cell carcinoma10.3CDKN2A, TNC
20rheumatoid arthritis10.3
21arthritis10.3
22lichtenstein syndrome10.3CD44, TP53
23large cell carcinoma with rhabdoid phenotype10.3ENO2, NF1
24headache10.3GFAP, MBP
25middle ear squamous cell carcinoma10.3CDKN2A, TP53
26sensory system cancer10.3GFAP, NF1, TP53
27hypothyroidism due to deficient transcription factors involved in pituitary development or function10.3GFAP, NF1, TP53
28anterior spinal artery syndrome10.3GFAP, NF1, TP53
29molluscum contagiosum10.3CDKN2A, TNC, TP53
30schwannoma of twelfth cranial nerve10.3CDKN2A, NF1, TP53
31anal paget's disease10.3CDKN2A, TP53
32primary malignant melanoma of the cervix10.3CDKN2A, PTEN
33subependymal giant cell astrocytoma10.3GFAP, TP53
34benign eccrine breast spiradenoma10.3CDKN2A, TNC, TP53
35borna disease10.3CDKN2A, GFAP, NF1
36childhood medulloblastoma10.3ENO2, GFAP
37eye disease10.3GFAP, TP53
38ovary neuroendocrine neoplasm10.3PTEN, TP53
39cervical adenosquamous carcinoma10.3CD44, CDKN2A
40anaplastic ganglioglioma10.3GFAP, PTEN
41skin glomus tumor10.3GFAP, PTEN
42form agnosia10.2ENO2, MBP
43intracystic papillary adenoma10.2ENO2, TP53
44cellular schwannoma10.2GFAP, MBP, NF1
45autosomal dominant medullary cystic kidney disease with hyperuricemia10.2CDKN2A, PTEN
46scabies10.2ENO2, TP53
47brachydactyly-arterial hypertension syndrome10.2ENO2, MBP
48salivary gland adenoid cystic carcinoma10.2CD44, GFAP, TP53
49corneal neovascularization10.2ENO2, NF1, TP53
50pyelonephritis10.2ENO2, NF1, TP53

Graphical network of the top 20 diseases related to Juvenile Pilocytic Astrocytoma:



Diseases related to juvenile pilocytic astrocytoma

Symptoms for Juvenile Pilocytic Astrocytoma

About this section

Drugs & Therapeutics for Juvenile Pilocytic Astrocytoma

About this section

Drugs for Juvenile Pilocytic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 152)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DonepezilapprovedPhase 3, Phase 2271120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil Hydrochloride
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
2
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
3
Vincristineapproved, investigationalPhase 2, Phase 3, Phase 18632068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
4
ProcarbazineapprovedPhase 2, Phase 368671-16-94915
Synonyms:
1-Methyl-2-(P-(isopropylcarbamoyl)benzyl)hydrazine
1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
2-(P-Isopropylcarbamoylbenzyl)-1-methylhydrazine
2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
366-70-1 (mono-hydrochloride)
4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
671-16-9
AC-4547
AC1L1J8E
Ambap671-16-9
BIDD:GT0183
BPBio1_001369
BRN 0958270
BSPBio_001244
Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)
C07402
C12H19N3O
CAS-366-70-1
CB 400-497
CCRIS 2389
CHEMBL1321
CID4915
D08423
DB01168
EINECS 211-582-2
HMS2090J09
HSDB 3250
I01-8931
IBZ
Ibenzmethyzin
Ibenzmethyzine
LS-7671
MBH
MIH
Matulane
MolPort-005-940-370
N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
 
N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide
N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
N-4-Isopropylcarbamoylbenzyl-n'-methylhydrazine
N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-P-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-alpha-(2-methylhydrazino)-P-toluamide
N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide
N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
NCGC00016438-01
NCGC00016438-02
NCI60_041703
NCIOpen2_004074
NSC-77213
Natulan
Natulanar
P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
PCX
Prestwick0_001112
Prestwick1_001112
Prestwick2_001112
Prestwick3_001112
Procarbazin
Procarbazin [German]
Procarbazina
Procarbazina [INN-Spanish]
Procarbazine (INN)
Procarbazine Monohydrochloride
Procarbazine [INN:BAN]
Procarbazine hydrochloride
Procarbazinum
Procarbazinum [INN-Latin]
Ro 4-6467
Ro 4-6467/1
SPBio_003112
SRI-10847
UNII-35S93Y190K
p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide
procarbazine
5
DopamineapprovedPhase 3308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6
LomustineapprovedPhase 2, Phase 37613010-47-43950
Synonyms:
(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
13010-47-4
AC-10564
AC1L1H2T
AI3-52779
BRN 2125058
Belustine
Bristol Myers Squibb Brand of Lomustine
Bristol-Myers Squibb Brand of Lomustine
C9H16ClN3O2
CCNU
CCNU [Chloroethyl nitrosoureas]
CCRIS 860
CHEMBL514
CID3950
CINU
Cecenu
CeeNU
CeeNU (TN)
CeeNU, CCNU, Lomustine
Ceenu
Chloroethylcyclohexylnitrosourea
Cyclohexyl chloroethyl nitrosourea
D00363
D008130
DB01206
EINECS 235-859-2
FT-0083566
Gleostine
 
HMS2090A17
HSDB 6519
I06-0087
ICIG 1109
LS-728
Lomustina
Lomustina [INN-Spanish]
Lomustine
Lomustine (USAN/INN)
Lomustine [USAN:BAN:INN]
Lomustine medac Brand
Lomustinum
Lomustinum [INN-Latin]
MolPort-001-768-818
N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
NCGC00167466-01
NCI-C04740
NCI60_041743
NCIMech_000220
NPFAPI-06
NSC 79037
NSC-79037
NSC79037
OR5087
RB 1509
Rhone Poulenc Rorer Brand of Lomustine
Rhone-Poulenc Rorer Brand of Lomustine
S1840_Selleck
SRI 2200
UNII-7BRF0Z81KG
WLN: L6TJ AMVNNO&2G
ZINC03831006
lomustine
medac Brand of Lomustine
7
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
8
Methylphenidateapproved, investigationalPhase 3364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
9
CyproheptadineapprovedPhase 315129-03-32913
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
129-03-3
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
41354-29-4
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
Biomol-NT_000131
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
CYPROHEPTADINE
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
Cyproheptadine (INN)
 
Cyproheptadine Hcl
Cyproheptadine Hydrochloride
Cyproheptadine [INN:BAN]
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
LS-114933
Lopac-C-6022
Lopac0_000246
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
nchembio.559-comp10
10Anesthetics, IntravenousPhase 31943
11Tubulin ModulatorsPhase 2, Phase 3, Phase 14279
12AnalgesicsPhase 39358
13Analgesics, OpioidPhase 32304
14AnestheticsPhase 37385
15Central Nervous System StimulantsPhase 3, Phase 21721
16Anesthetics, GeneralPhase 32274
17NarcoticsPhase 32709
18Antineoplastic Agents, PhytogenicPhase 2, Phase 3, Phase 1, Phase 04294
19Central Nervous System DepressantsPhase 310016
20Liver ExtractsPhase 3, Phase 2, Phase 13572
21Antimitotic AgentsPhase 2, Phase 3, Phase 14296
22Cholinesterase InhibitorsPhase 3, Phase 2498
23Cholinergic AgentsPhase 3, Phase 23243
24Peripheral Nervous System AgentsPhase 318510
25Neurotransmitter AgentsPhase 3, Phase 214795
26Nootropic AgentsPhase 3, Phase 2604
27pancreatic polypeptidePhase 3, Phase 120
28Dermatologic AgentsPhase 3, Phase 2, Phase 14555
29Dopamine AgentsPhase 33084
30Dopamine Uptake InhibitorsPhase 3925
31Serotonin AntagonistsPhase 31175
32Neurotransmitter Uptake InhibitorsPhase 32857
33Dexmethylphenidate HydrochloridePhase 316
34Histamine H1 AntagonistsPhase 3688
35Anti-Allergic AgentsPhase 31312
36Serotonin AgentsPhase 32668
37AntipruriticsPhase 3619
38Gastrointestinal AgentsPhase 36401
39
SerotoninPhase 3314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
40Histamine AntagonistsPhase 3826
41
histaminePhase 390675614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
42ColaNutraceuticalPhase 3, Phase 11768
43
Dacarbazineapproved, investigationalPhase 2, Phase 14114342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
44
Topotecanapproved, investigationalPhase 2330119413-54-660700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
MLS000759456
 
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
45
CarboplatinapprovedPhase 2, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
46
TamoxifenapprovedPhase 235010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Soltamox
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
47
Irinotecanapproved, investigationalPhase 1, Phase 2104497682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
48
Modafinilapproved, investigationalPhase 219268693-11-84236
Synonyms:
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
 
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
49
Doxorubicinapproved, investigationalPhase 2, Phase 0158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
50
CisplatinapprovedPhase 2, Phase 1254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)

Interventional clinical trials:

(show top 50)    (show all 66)
idNameStatusNCT IDPhase
1Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
2Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain TumorsCompletedNCT00369785Phase 3
3Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade GliomaActive, not recruitingNCT00003375Phase 2, Phase 3
4Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerTerminatedNCT01132547Phase 3
5Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain TumorsTerminatedNCT00031798Phase 3
6Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00112736Phase 1, Phase 2
7Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain TumorsCompletedNCT01032200Phase 2
8Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord TumorsCompletedNCT00541138Phase 2
9Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant GliomaCompletedNCT00498927Phase 2
10Temozolomide in Treating Patients With Low-Grade GliomaCompletedNCT00313729Phase 2
11Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for GliomasCompletedNCT00274755Phase 2
12Donepezil or EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain MetastasesCompletedNCT00070161Phase 2
13Imatinib Mesylate in Treating Patients With GliomasCompletedNCT00039364Phase 2
14Gefitinib in Treating Patients With Recurrent or Progressive CNS TumorsCompletedNCT00025675Phase 2
15Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaCompletedNCT00010049Phase 1, Phase 2
16Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade GliomaCompletedNCT00003467Phase 2
17Temozolomide in Treating Patients With Progressive Low-Grade GliomaCompletedNCT00003466Phase 2
18Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain TumorsCompletedNCT00003461Phase 1, Phase 2
19Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain CancersCompletedNCT00002752Phase 1, Phase 2
20Combination Chemotherapy and Tamoxifen in Treating Patients With Solid TumorsCompletedNCT00002608Phase 2
21Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway GliomaRecruitingNCT01553149Phase 2
22Phase II Pegylated InterferonRecruitingNCT02343224Phase 2
23A Phase I Study of Mebendazole for the Treatment of Pediatric GliomasRecruitingNCT01837862Phase 1, Phase 2
24Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerRecruitingNCT00445965Phase 2
25Antineoplaston Therapy in Treating Patients With Brain TumorsRecruitingNCT00003457Phase 2
26Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade GliomaActive, not recruitingNCT01089101Phase 1, Phase 2
27Photodynamic Therapy (PDT) For Recurrent High Grade GliomasActive, not recruitingNCT01966809Phase 2
28Bevacizumab in Recurrent Grade II and III GliomaActive, not recruitingNCT01164189Phase 2
29Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT00553150Phase 1, Phase 2
30Antineoplaston Therapy in Treating Patients With Low-Grade AstrocytomaActive, not recruitingNCT00003471Phase 2
31Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaActive, not recruitingNCT00939770Phase 1, Phase 2
32Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain TumorsWithdrawnNCT00005083Phase 2
33RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
34Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
35Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to TreatmentCompletedNCT00544284Phase 1
36Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00509431Phase 1
37Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other CancersCompletedNCT00498979Phase 1
38BCX-1777 in Treating Patients With Refractory CancerCompletedNCT00073944Phase 1
39Thalidomide and Docetaxel in Treating Patients With Advanced CancerCompletedNCT00049296Phase 1
40MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00020579Phase 1
41Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory LymphomasCompletedNCT00019019Phase 1
42Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00008086Phase 1
43Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1
44Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain TumorsCompletedNCT00003484Phase 1
45Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal CancerCompletedNCT00003022Phase 1
46Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or LymphomaCompletedNCT01273090Phase 1
47Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasRecruitingNCT02186509Phase 1
48Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain TumorsRecruitingNCT00002647Phase 1
49Photodynamic Therapy (PDT) for Brain TumorsActive, not recruitingNCT01682746Phase 1
50Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial GliomasActive, not recruitingNCT00083096Phase 1

Search NIH Clinical Center for Juvenile Pilocytic Astrocytoma

Genetic Tests for Juvenile Pilocytic Astrocytoma

About this section

Anatomical Context for Juvenile Pilocytic Astrocytoma

About this section

MalaCards organs/tissues related to Juvenile Pilocytic Astrocytoma:

33
Brain, Liver, Kidney, Spinal cord, Lung, Testes, Monocytes

Animal Models for Juvenile Pilocytic Astrocytoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Juvenile Pilocytic Astrocytoma:

38 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053778.5MAP2K1, MAPK3, MBP, NF1, TNC, TP53
2MP:00020068.4CD44, CDKN2A, MAP2K1, MAPK3, NF1, PTEN
3MP:00028738.2CD44, GFAP, MAP2K1, MBP, NF1, PTEN
4MP:00053708.2CD44, CDKN2A, INSR, MAPK3, NF1, PTEN
5MP:00053798.1CD44, CDKN2A, INSR, MAP2K1, MAPK3, NF1
6MP:00107718.1CD44, CDKN2A, MAP2K1, MAPK3, NF1, PTEN
7MP:00053697.9CD44, CDKN2A, GFAP, INSR, MAPK3, NF1
8MP:00053887.8CD44, CDKN2A, ENO2, INSR, MAPK3, NF1
9MP:00053817.7CD44, CDKN2A, GFAP, INSR, MAP2K1, MAPK3
10MP:00053917.4CD44, CDKN2A, GFAP, MAP2K1, MAPK3, MBP
11MP:00053857.1CD44, CDKN2A, GFAP, INSR, MAP2K1, MAPK3
12MP:00107686.9CD44, CDKN2A, GFAP, INSR, MAP2K1, MAPK3
13MP:00053766.7CD44, CDKN2A, GFAP, INSR, MAP2K1, MAPK3
14MP:00053976.7CD276, CD44, CDKN2A, INSR, MAPK3, MBP
15MP:00053846.7CD44, CDKN2A, ENO2, GFAP, INSR, MAP2K1
16MP:00053786.7CD44, CDKN2A, ENO2, GFAP, INSR, MAP2K1
17MP:00053866.6CD44, CDKN2A, ENO2, GFAP, INSR, MAPK3
18MP:00036316.3CD44, CDKN2A, ENO2, GFAP, INSR, MAP2K1
19MP:00053876.1CD276, CD44, CDKN2A, GFAP, INSR, MAPK3

Publications for Juvenile Pilocytic Astrocytoma

About this section

Articles related to Juvenile Pilocytic Astrocytoma:

(show all 46)
idTitleAuthorsYear
1
Complications Following Surgery for Gastroesophageal Reflux Disease and Achalasia. (26515948)
2015
2
Does self-construal predict activity in the social brain network? A genetic moderation effect. (24009354)
2014
3
Activation of p53 transcriptional activity by SMRT: a histone deacetylase 3-independent function of a transcriptional corepressor. (24449765)
2014
4
Perceptions and acceptability of mHealth interventions for improving patient care at a community-based HIV/AIDS clinic in Uganda: a mixed methods study. (23452084)
2013
5
Autologous tenocyte implantation, a novel treatment for partial-thickness rotator cuff tear and tendinopathy in an elite athlete. (23314880)
2013
6
Rare association of cutaneous vasculitis, IgA nephropathy and antiphospholipid antibody syndrome with tuberculous lymphadenitis. (23917677)
2013
7
High-dose magnesium sulfate infusion protocol for status asthmaticus: a safety and pharmacokinetics cohort study. (23129148)
2013
8
Three-dimensional echocardiographic evaluation of an anterior mitral leaflet perforation and aortic vegetation due to infective endocarditis. (23128553)
2013
9
Experimental model of biofilm implant-related osteomyelitis to test combination biomaterials using biofilms as initial inocula. (22492534)
2012
10
Retinal functional changes measured by microperimetry after immunosuppressive therapy in patients with Vogt-Koyanagi-Harada disease. (21928252)
2012
11
Circulation of QX-like infectious bronchitis virus in the Middle East. (23042850)
2012
12
LOHA 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation. (22992787)
2012
13
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. (19886911)
2010
14
A decreased ratio of laminin-332 beta3 to gamma2 subunit mRNA is associated with poor prognosis in colon cancer. (19383890)
2009
15
Small cell carcinoma of the prostate. (19095268)
2009
16
Alitretinoin: a comprehensive review. (18321241)
2008
17
Altered venous capacitance as a cause of postprandial hypotension in multiple system atrophy. (17139443)
2007
18
Difficulties in diagnosing febrile states in 21-month-old patient: case report]. (18434975)
2007
19
Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method. (17034136)
2006
20
Oxidative modification of human ceruloplasmin by methylglyoxal: an in vitro study. (16756764)
2006
21
Zinc-finger transcription factor Gfi-1: versatile regulator of lymphocytes, neutrophils and hematopoietic stem cells. (16319680)
2006
22
Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. (15855637)
2005
23
Chalcones as potent tyrosinase inhibitors: the importance of a 2,4-substituted resorcinol moiety. (15598564)
2005
24
A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. (15680154)
2005
25
Neuroschistosomiasis due to Schistosoma mansoni: a review of pathogenesis, clinical syndromes and diagnostic approaches. (16138195)
2005
26
Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. (12807231)
2003
27
A novel locus for Meckel-Gruber syndrome, MKS3, maps to chromosome 8q24. (12384791)
2002
28
Thanatophoric dysplasia type I. (11270184)
2001
29
Significance of genetic testing for paternal uniparental disomy of chromosome 6 in neonatal diabetes mellitus. (9880447)
1999
30
Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. (9620803)
1998
31
Fluorescence in situ hybridization characterization of the chromosomal breakpoints in a case with ins(17;3)(q11.2;q21q26.3) and acute monocytic leukemia. (9797776)
1998
32
Perlman syndrome: a case report emphasizing its similarity to and distinction from Beckwith-Wiedemann and prune-belly syndromes. (9561541)
1998
33
Wound myiasis of sheep in Hungary. (9187038)
1997
34
Fibroblast chemotaxis and prolidase activity modulation by insulin-like growth factor II and mannose 6-phosphate. (9062907)
1997
35
Gastric outlet obstruction caused by prepyloric web in a case of Down's syndrome. (8887105)
1996
36
Purification and identification of a novel and four known serine proteinase inhibitors secreted by human glioblastoma cells. (8882727)
1996
37
Distribution pattern of computed tomography findings in patients with bronchiolitis obliterans organizing pneumonia. (8724121)
1996
38
Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. (8521295)
1995
39
Amplification of plasmid and chromosome Chlamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies. (7612032)
1995
40
The effects of naloxone on retinal ischemia in rats. (8083567)
1994
41
Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhinitis measured by eosinophil cationic protein levels in native nasal fluid and serum. (7889429)
1994
42
Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. (8406993)
1993
43
Selective removal of glycosylation sites from sex hormone-binding globulin by site-directed mutagenesis. (1425432)
1992
44
Experimental coccidiosis in goats. 2. Effect of parasitism on nutritional balances and some blood parameters. (3777812)
1986
45
PARANOID SCHIZOPHRENIA IN A PATIENT WITH KLINEFELTER'S SYNDROME. (14220862)
1964
46
DISCUSSION ON THE AETIOLOGY AND TREATMENT OF IRITIS. (19979872)
1917

Variations for Juvenile Pilocytic Astrocytoma

About this section

Expression for genes affiliated with Juvenile Pilocytic Astrocytoma

About this section
Search GEO for disease gene expression data for Juvenile Pilocytic Astrocytoma.

Pathways for genes affiliated with Juvenile Pilocytic Astrocytoma

About this section

Pathways related to Juvenile Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 34)
idSuper pathwaysScoreTop Affiliating Genes
19.7MAP2K1, MAPK3
2
Show member pathways
9.5MAP2K1, MAPK3, NF1
39.5INSR, MAP2K1, MAPK3
49.4MAP2K1, MAPK3, TP53
59.4MAP2K1, MAPK3, TP53
69.4MAP2K1, MAPK3, TP53
79.4CDKN2A, MAPK3, TP53
8
Show member pathways
9.2MAP2K1, MAPK3, PTEN
9
Show member pathways
9.2INSR, MAP2K1, MAPK3, TP53
109.1CDKN2A, MAP2K1, MAPK3, TP53
11
Show member pathways
9.1CDKN2A, MAP2K1, MAPK3, TP53
12
Show member pathways
9.1CDKN2A, MAP2K1, MAPK3, TP53
13
Show member pathways
9.1MAP2K1, MAPK3, MBP, TP53
14
Show member pathways
9.1CD44, MAP2K1, MAPK3, NF1
159.0GFAP, MAPK3, MBP, TP53
169.0CD44, MAP2K1, MAPK3, TP53
17
Show member pathways
8.9INSR, MAPK3, PTEN, TP53
188.9INSR, MAP2K1, MAPK3, PTEN
19
Show member pathways
8.9INSR, MAP2K1, MAPK3, PTEN
208.9ENO2, INSR, MAP2K1, MAPK3
218.9MAP2K1, MAPK3, PTEN, TP53
22
Show member pathways
8.9MAP2K1, MAPK3, PTEN, TP53
23
Show member pathways
8.9MAP2K1, MAPK3, PTEN, TP53
248.9MAP2K1, MAPK3, PTEN, TP53
25
Show member pathways
8.9MAP2K1, MAPK3, PTEN, TP53
268.9MAP2K1, MAPK3, PTEN, TP53
27
Show member pathways
8.6MAP2K1, MAPK3, PTEN, TP53
28
Show member pathways
8.6INSR, MAP2K1, MAPK3, PTEN, TP53
298.6CD44, CDKN2A, MAP2K1, PTEN, TP53
308.6CDKN2A, MAP2K1, MAPK3, PTEN, TP53
318.4INSR, MAP2K1, MAPK3, PTEN, TNC, TP53
328.4CD44, CDKN2A, MAP2K1, PTEN, TNC, TP53
33
Show member pathways
8.3CDKN2A, MAP2K1, MAPK3, NF1, PTEN, TP53
348.3CDKN2A, MAP2K1, MAPK3, NF1, PTEN, TP53

GO Terms for genes affiliated with Juvenile Pilocytic Astrocytoma

About this section

Biological processes related to Juvenile Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of cell-matrix adhesionGO:000195310.4CDKN2A, NF1
2regulation of Golgi inheritanceGO:009017010.3MAP2K1, MAPK3
3regulation of axon regenerationGO:004867910.2MAP2K1, PTEN
4regulation of synaptic transmission, GABAergicGO:003222810.1NF1, PTEN
5cell cycle arrestGO:000705010.0CDKN2A, MAP2K1, TP53
6negative regulation of axonogenesisGO:00507719.9MBP, PTEN
7replicative senescenceGO:00903999.7CDKN2A, TP53
8activation of MAPK activityGO:00001879.7INSR, MAP2K1, MAPK3
9Ras protein signal transductionGO:00072659.4CDKN2A, MAP2K1, MAPK3
10fibroblast growth factor receptor signaling pathwayGO:00085439.0MAP2K1, MAPK3, NF1, PTEN
11neurotrophin TRK receptor signaling pathwayGO:00480118.9MAP2K1, MAPK3, NF1, PTEN

Sources for Juvenile Pilocytic Astrocytoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet